Literature DB >> 8182529

The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats.

S M Sadrzadeh1, A A Nanji, P L Price.   

Abstract

The effect of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on liver nonheme iron, lipid peroxidation and hepatic fat accumulation in the intragastric feeding rat model for alcoholic liver disease was studied. Male Wistar rats (225-250 g) were fed liquid diet and ethanol for 1 month. In control pair-fed animals, ethanol was replaced isocalorically by dextrose. Two additional groups of animals (dextrose and ethanol-fed) received L1 (75 mg/kg/day for 30 days). The blood ethanol level in the ethanol-fed animals was maintained between 150 and 350 mg/dl. For each animal, the levels of hepatic nonheme iron, lipid peroxidation and triglyceride were evaluated. The nonheme iron in alcohol-fed animals was significantly higher (416 +/- 15 nmol/g of liver) than in pair-fed dextrose controls (346 +/- 18.5 nmol/g, P < .05). Animals fed ethanol and L1 had significantly lower nonheme iron (364 +/- 9.3 nmol/g) than rats fed ethanol alone (P < .05). L1 had no effect on nonheme iron levels in dextrose-fed controls. The importance of iron in lipid peroxidation in this model is shown by the positive correlation between the nonheme iron levels and microsomal conjugated dienes (r = 0.67, P < .02) and liver thiobarbituric acid reactive substances (r = 0.62, P < .05). The most significant observations in this study were: 1) the higher hepatic nonheme iron content in ethanol-fed rats compared to pair-fed dextrose controls; 2) lower nonheme iron and liver fat in the ethanol-fed rats treated with L1; and 3) the significant positive correlation between the liver nonheme and lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182529

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases.

Authors:  Jessica A Williams; Sharon Manley; Wen-Xing Ding
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 2.  Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

Review 3.  "Second hit" models of alcoholic liver disease.

Authors:  Hidekazu Tsukamoto; Keigo Machida; Alla Dynnyk; Hasmik Mkrtchyan
Journal:  Semin Liver Dis       Date:  2009-04-22       Impact factor: 6.115

4.  Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis.

Authors:  Shigang Xiong; Hongyun She; An-Sheng Zhang; Jiaohong Wang; Hasmik Mkrtchyan; Alla Dynnyk; Victor R Gordeuk; Samuel W French; Caroline A Enns; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-07-03       Impact factor: 4.052

5.  Inhibition of NF-κB activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease.

Authors:  Xiaobing Dou; Songtao Li; Zhigang Wang; Dongfang Gu; Chen Shen; Tong Yao; Zhenyuan Song
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

Review 6.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets.

Authors:  Long-Xia Li; Fang-Fang Guo; Hong Liu; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2022-03-24       Impact factor: 9.261

Review 8.  Apoptosis and necrosis: two types of cell death in alcoholic liver disease.

Authors:  A A Nanji; S Hiller-Sturmhöfel
Journal:  Alcohol Health Res World       Date:  1997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.